Evaluation of the hepatotoxic potential of citalopram in rats
ISTANBUL JOURNAL OF PHARMACY, cilt.50, sa.3, ss.188-194, 2020 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 50 Sayı: 3
- Basım Tarihi: 2020
- Doi Numarası: 10.26650/istanbuljpharm.2019.0081
- Dergi Adı: ISTANBUL JOURNAL OF PHARMACY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.188-194
- Anahtar Kelimeler: Citalopram, hepatotoxicity, hepatic biomarker, liver histology, oxidative status, INDUCED LIVER-INJURY, SEROTONIN REUPTAKE INHIBITORS, DRUG, ANTIDEPRESSANTS, ESCITALOPRAM, METABOLITES, MECHANISMS, DIAGNOSIS, PLACEBO
- Eskişehir Osmangazi Üniversitesi Adresli: Evet
Özet
Background and Aims: Citalopram is a selective serotonin reuptake inhibitor with a high potency which is occasionally prescribed and used to treat major depression associated with mood disorders as a first-line drug. According to the results of previous studies, evidence of hepatotoxicity related to citalopram treatment were limited and conflicting. Therefore, we aimed to evaluate the hepatotoxicity potential of sub-chronic citalopram administration.